Subject 1 (S1), presented at age 34yrs with oligomenorrhoea and subfertility, when dyslipidaemia was found. At age 41, partial lipodystrophy was noted; type 2 diabetes was diagnosed and diet-treated. She has developed severe three vessel coronary artery disease that was not alleviated by percutaneous revascularisation and is on triple antianginal therapy. She is heterozygous for a cysteine to arginine mutation at codon 114 (C114R) in PPARγ1 and her mother and sister are genetically unaffected with normal biochemistry; her father (genotype unknown) died age 60yrs from a myocardial infarction.
dyslipidaemic (fasting insulin [FI] 168 pmol/L; triglycerides [TG] 8.6mmol/L, high density lipoprotein cholesterol [HDL-C] 1.0mmol/L), whereas an unaffected older sister is biochemically normal (FI 79 pmol/L; TG 0.8mmol/L, HDL-C 1.4mmol/L). Her genetically affected father was a long-term smoker and deceased from lung carcinoma.
Subject 3 (S3), presented at age 19yrs with eruptive xanthomata secondary to severe hypertriglyceridaemia. Retrospectively, partial lipodystrophy was present since age 8, PCOS was diagnosed in her twenties and hypertension and acanthosis nigricans together with impaired glucose tolerance were noted age 29yrs. She is heterozygous for a cysteine to tryptophan mutation at codon 162 (C162W) in PPARγ1. Significant hypertriglyceridaemia (TG 26mmol/L) has been diagnosed since age 49yrs in her genetically affected mother together with hypertension, type 2 diabetes and ischaemic heart disease age 52yrs; her genetically affected grandfather has type 2 diabetes and ischaemic heart disease.
Subject 4 (S4), presented at age 8yrs with diabetes mellitus and partial lipodystrophy, acanthosis nigricans and severe hypertriglyceridaemia with eruptive xanthomata were noted; she is currently on metformin, pioglitazone and insulin therapy. She is heterozygous for a frameshift mutation predicting a premature stop mutation at codon Subject 5 (S5), presented at age 26yrs with gestational diabetes and hypertension and pregnancy was complicated by preeclampsia. Type 2 diabetes and hypertension persisted post-partum and dyslipidaemia was noted subsequently leading to episodes of pancreatitis. Partial lipodystrophy and acanthosis nigricans were present. Treatment includes metformin, fenofibrate and insulin. She is heterozygous for a mutation changing arginine at codon 357 to a stop mutation (R357X). Her deceased mother, who was found to be genetically affected retrospectively, developed hypertension in her thirties, type 2 diabetes and dyslipidaemia (TG 4.9mmol/L, HDL-C 0.6mmol/L) in her forties and died suddenly from cardiovascular cause age 57. Figure S1 . T1-weighted MRI scans at the level of the gluteal fat pad in PPARγ mutation carriers and a gender-matched healthy control subject. Note the striking diminution of the gluteal fat depot in all probands (S1-S5) with PPARγ mutations.
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